CDH2 and ovarian carcinoma: Collectively, the single-cell transcriptomic analysis of clinical ovarian cancer samples suggests that elevated CDH2 expression may contribute to cisplatin resistance by promoting epithelial–mesenchymal transition (EMT), enhancing cell–matrix interactions, and activating pro-survival signaling pathways.